94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Oncol.
Sec. Pharmacology of Anti-Cancer Drugs
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1588836
This article is part of the Research TopicEvidence-Based Research and Clinical Application of Adverse Reactions and Management Strategies for Cancer Treatment DrugsView all articles
Analysis of three treatment methods for granulomatous lobular mastitis: A retrospective study in a single center
Provisionally accepted- First Affiliated Hospital of Harbin Medical University, Harbin, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Granulomatous lobular mastitis (GLM) is a rare, benign inflammatory condition of the breast that is difficult to distinguish from breast cancer on the basis of clinical and imaging findings. GLM typically has a long disease course, and is difficult to treat and prone to recurrence. Furthermore, there is currently no standard treatment for GLM. The aim of this study was to compare the therapeutic effects and patient satisfaction scores of surgery, triple anti-tuberculosis drug therapy, and combination treatment against GLM.Methods: The medical records and follow-up data of GLM patients who underwent treatment at our center were retrospectively analyzed. Patients were divided into the treatment groups of surgery (group A), triple anti-tuberculosis drug therapy (group B), and combination therapy (group C). The demographic and clinical data, treatment outcomes, and patient satisfaction scores were compared among the three groups.Results: Median follow-up duration of the patients was 35.43 months (range, 13.27-67.90 months). There were 106, 109, and 88 patients in groups A, B, and C respectively. The cure rates were similar among the groups (P = 0.220), although treatment duration was longest for group B, followed by group C and group A (P < 0.001). Group B had the highest patient satisfaction scores (P < 0.001),whereas the recurrence rate was highest in Group A (P < 0.001). Furthermore, no severe adverse drug reactions or major postoperative complications were observed in any of the patients. 缩进: 右侧: 0 毫米 设置格式[Author]: 字体: (默认) Times New Roman, 小四, 图案: 清除(白色), (中文)德语(瑞士) 设置格式[Author]: [在此处键入] 3 Conclusions: Triple anti-tuberculosis drug therapy can effectively treat GLM patients with high patient satisfaction scores for potential application in clinical practice. The combination of surgery and triple anti-tuberculosis drug therapy is a suitable option for patients seeking rapid relief. Trial registration: The study was registered at the Us Clinical Trial Registration Center
Keywords: Granulomatous lobular mastitis, Clinical presentation, surgical treatment, Triple anti-tuberculosis drug therapy, Treatment methods
Received: 06 Mar 2025; Accepted: 10 Apr 2025.
Copyright: © 2025 Shang, Zhang, Liu, Lu, Cui, Feng and Zhou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Jing Feng, First Affiliated Hospital of Harbin Medical University, Harbin, China
Yi Zhou, First Affiliated Hospital of Harbin Medical University, Harbin, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.